Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M7,780Revenue $M2,338Net Margin (%)15.7Altman Z-Score6.3
Enterprise Value $M7,715EPS $2.1Operating Margin %19.7Piotroski F-Score6
P/E(ttm)21.0Beneish M-Score-2.7Pre-tax Margin (%)19.6Higher ROA y-yY
Price/Book4.010-y EBITDA Growth Rate %31.0Quick Ratio1.5Cash flow > EarningsY
Price/Sales2.75-y EBITDA Growth Rate %36.7Current Ratio1.9Lower Leverage y-yY
Price/Free Cash Flow15.0y-y EBITDA Growth Rate %13.9ROA % (ttm)12.3Higher Current Ratio y-yN
Dividend Yield %0.7PEG0.6ROE % (ttm)20.9Less Shares Outstanding y-yN
Payout Ratio %14.0Shares Outstanding M171ROIC % (ttm)20.3Gross Margin Increase y-yY

Gurus Latest Trades with RDY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RDYKen Fisher 2016-03-31 Add0.02%$41.22 - $48.86
($44.64)
$ 45.602%Add 6.00%4,775,345
RDYKen Fisher 2015-12-31 Reduce-0.06%$43.55 - $67.79
($54.62)
$ 45.60-17%Reduce -9.20%4,504,956
RDYKen Fisher 2015-09-30 Reduce-0.03%$55.59 - $67.73
($62.11)
$ 45.60-27%Reduce -4.55%4,961,550
RDYKen Fisher 2015-06-30 Reduce$51.8 - $60.54
($55.23)
$ 45.60-17%Reduce -0.34%5,198,254
RDYKen Fisher 2015-03-31 Add0.12%$47.73 - $57.1
($53.03)
$ 45.60-14%Add 25.58%5,216,225
RDYKen Fisher 2014-06-30 Add0.13%$38.67 - $46.08
($42.03)
$ 45.608%Add 62.43%3,773,114
RDYKen Fisher 2014-03-31 Add0.08%$39.5 - $47.4
($43.29)
$ 45.605%Add 56.30%2,322,863
RDYKen Fisher 2013-06-30 Add0.04%$32.98 - $38.7
($36.5)
$ 45.6025%Add 48.42%1,283,605
RDYKen Fisher 2013-03-31 Add0.02%$32.03 - $36.57
($34.21)
$ 45.6033%Add 31.46%864,830
RDYKen Fisher 2012-09-30 Buy 0.05%$28.94 - $32.58
($30.12)
$ 45.6051%New holding604,555
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RDY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


RDY: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about RDY:

    News about RDY:

    Articles On GuruFocus.com
    Ken Fisher Sells Shares of PMC Sierra, Alphabet During 4th Quarter Jan 15 2016 
    Emerging Market Stocks To Watch Out For Feb 17 2015 
    Should You Buy Actavis? Mar 18 2014 
    Dr. Reddy’s Laboratories: Should Continue to Gain Market Share in Lucrative Markets May 25 2012 
    5 Mid-Cap Healthcare Dividend Stocks with Perfect Earnings Growth Dec 05 2011 
    Abbott Laboratories and the “India Cure” for the Ailing Pharmaceutical Industry May 26 2010 

    More From Other Websites
    Earnings Call Notification Apr 26 2016
    Dr. Reddy's to Release Q4 and Full Year FY16 Results on May 12, 2016; Earnings Call Slated for May... Apr 26 2016
    Management Council Apr 25 2016
    ZEMBRACE™ SymTouch™ (Sumatriptan Injection) 3 mg, Approved by the FDA in January 2016 for the... Apr 19 2016
    ZEMBRACE™ SymTouch™ (Sumatriptan Injection) 3 mg, Approved by the FDA in January 2016 for the... Apr 19 2016
    How Have India’s Industry and Services Sectors Performed? Apr 19 2016
    China Takes a Breather as India Drives Growth in Asia Apr 07 2016
    Investing in Indian Stocks: Active versus Passive Modes Apr 05 2016
    Not a Good 1Q16 for Indian Stocks, but Is the Tide Turning? Apr 05 2016
    Cutispharma, Dr. Reddy's Laboratories Announce Partnership Apr 05 2016
    Dr. Reddy's Acquires Anticancer Drug Rights from Eisai Apr 01 2016
    Dr. Reddy’s Laboratories Acquires the Rights to Investigational Anticancer Agent E7777 for U.S,... Mar 31 2016
    Dr. Reddy’s Laboratories Acquires the Rights to Investigational Anticancer Agent E7777 for U.S.,... Mar 31 2016
    Dr. Reddy’s Laboratories Acquires the Rights to Investigational Anticancer Agent E7777 for U.S.,... Mar 31 2016
    Eisai Transfer the Rights to Investigational Anticancer Agent E7777 for European, U.S and Certain... Mar 31 2016
    Dr Reddy's Collaborates with XenoPort for Psoriasis Drug Mar 28 2016
    Dr. Reddy’s Laboratories and XenoPort Enter Into a U.S. Licensing Agreement for XP23829 Mar 28 2016
    Dr. Reddy’s Laboratories and XenoPort Enter into a U.S. Licensing Agreement for XP23829 Mar 28 2016
    Dr. Reddy’s Laboratories and XenoPort Enter into a U.S. Licensing Agreement for XP23829 Mar 28 2016
    Dr. Reddy’s and TR-Pharm Announce Strategic Collaboration in Turkey Mar 11 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)